Harlan Weisman

Harlan Weisman, M.D.

Vice Chairman of the Board

Harlan F. Weisman, M.D. has more than 30 years experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Dr. Weisman is Executive Chairman of 3DBio Therapeutics and on the Board of Directors of TFF Pharmaceuticals, Perla Therapeutics and the Center for Discovery and Innovation, Hackensack Meridian Health.  He is an Operating Partner at CRG, a healthcare investment firm and is a Venture Advisor to the Israel Biotech Fund. He is on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences and the Memorial Sloan Kettering Cancer Center Technology Development Fund.  From 2010 to 2016 Dr. Weisman served on the Board of Governors of the Patient Centered Outcomes Research Institute (PCORI), established by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010.

Dr. Weisman graduated from the University of Maryland with High Honors and the University of Maryland School of Medicine Cum Laude. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he was a fellow in cardiovascular disease at Johns Hopkins Hospital, and was then appointed as Assistant Professor of Medicine at Johns Hopkins University School of Medicine, Consultant Cardiologist, Johns Hopkins Hospital, and Director of the Experimental Cardiac Pathology Laboratory.

Dr. Weisman was recruited from Johns Hopkins to Centocor, Inc., where he pioneered monoclonal antibodies as medical breakthroughs for wide therapeutic applications, including ReoPro®, REMICADE®, Simponi® and STELARA® which have combined annual sales of >$8 Billion. He was the head of R&D when Johnson & Johnson acquired Centocor in 1999. He then became President of J&J Pharmaceutical R&D, where he mobilized and inspired the organization to improve pipeline performance and accelerate growth by advancing >15 new molecular entities into late-stage development within 3 years, and gaining approvals of 10 drugs with >$15 Billion in annual sales. Dr. Weisman was promoted to Company Group Chairman, Pharmaceutical R&D, and had executive oversight of ALZA Corporation and J&J Pharmaceutical R&D, and led the acquisition and integration of 3-Dimensional Pharmaceuticals and later TransForm Pharmaceuticals. In this role, he managed a complex, multidisciplinary R&D organization with a $7.3 Billion R&D budget and >6,000 R&D employees in 12 research centers across the globe.

In 2006, Dr. Weisman was appointed Chief Science and Technology Officer of Medical Devices and Diagnostics, where he steered the medical, regulatory, scientific and technology agendas for the J&J Medical Device and Diagnostics Group, including investments in drug/biologics-device combination products, regenerative medicine, nanotechnology and health informatics. He directed the effort to open a new innovation center in China, which is developing a rich pipeline of products for emerging markets. Dr. Weisman also built new capabilities in Regulatory Affairs and Evidence Based Medicine and was on the Board of Directors of J&J Development Corporation.

Dr. Weisman has a strong track record of building organizational capabilities, creating cultures of innovation and developing leaders and teams. He laid the groundwork for sustaining success at J&J by recruiting and developing world-class, high-potential leaders at multiple layers within the organization.

Dr. Weisman is a Fellow of the American College of Cardiology, the American College of Chest Physicians, and the American Heart Association and is a member of the American College of Physicians and the American Medical Association. He is an author of more than 100 articles and book chapters in the fields of cardiovascular disease, medical product development, healthcare policy and organizational development. Dr. Weisman has been an invited speaker at international meetings on medical innovation, health policy and product development strategy and been the recipient of numerous awards for contributions in clinical medicine, research and innovation.